Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Modulation of Phenotype and Function of Human CD4+CD25+ T Regulatory Lymphocytes Mediated by cAMP-Elevating Agents.

Riccomi A, Gesa V, Sacchi A, De Magistris MT, Vendetti S.

Front Immunol. 2016 Sep 20;7:358. eCollection 2016.

2.

Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.

Sciaraffia E, Riccomi A, Lindstedt R, Gesa V, Cirelli E, Patrizio M, De Magistris MT, Vendetti S.

J Leukoc Biol. 2014 Jul;96(1):113-22. doi: 10.1189/jlb.3A0513-302RR. Epub 2014 Mar 20.

3.

The Innovative Medicines Initiative moves translational immunology forward.

Goldman M, Wittelsberger A, De Magistris MT.

Eur J Immunol. 2013 Feb;43(2):298-302. Review.

PMID:
23534061
4.

Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells.

Veglia F, Sciaraffia E, Riccomi A, Pinto D, Negri DR, De Magistris MT, Vendetti S.

Infect Immun. 2011 Mar;79(3):1300-10. doi: 10.1128/IAI.01181-10. Epub 2010 Dec 13.

5.

Polyclonal Treg cells enhance the activity of a mucosal adjuvant.

Vendetti S, Davidson TS, Veglia F, Riccomi A, Negri DR, Lindstedt R, Pasquali P, Shevach EM, De Magistris MT.

Immunol Cell Biol. 2010 Oct;88(7):698-706. doi: 10.1038/icb.2010.76. Epub 2010 Jun 29.

PMID:
20585335
6.

Persistence of mucosal and systemic immune responses following sublingual immunization.

Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, Cicconi R, Ruggiero P, Del Giudice G, De Magistris MT.

Vaccine. 2010 Jun 7;28(25):4175-80. doi: 10.1016/j.vaccine.2010.04.013. Epub 2010 Apr 21.

PMID:
20412876
7.

European Union conference on poverty-related diseases research.

Gryseels B, Zumla A, Troye-Blomberg M, Kieny MP, Quaglio G, Holtel A, Laang H, Romaris M, De Magistris MT, Nuez AN, Olesen OF, Ghalouci R, Lönnroth A.

Lancet Infect Dis. 2009 Jun;9(6):334-7. doi: 10.1016/S1473-3099(09)70129-X. No abstract available.

PMID:
19467472
8.

Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization.

Vendetti S, Riccomi A, Negri DR, Veglia F, Sciaraffia E, De Magistris MT.

Methods. 2009 Dec;49(4):334-9. doi: 10.1016/j.ymeth.2009.04.018. Epub 2009 May 6.

PMID:
19426804
9.

Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes.

Negri DR, Pinto D, Vendetti S, Patrizio M, Sanchez M, Riccomi A, Ruggiero P, Del Giudice G, De Magistris MT.

Infect Immun. 2009 May;77(5):1924-35. doi: 10.1128/IAI.01559-08. Epub 2009 Feb 17.

10.

Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28.

Vendetti S, Riccomi A, Sacchi A, Sciaraffia E, Gatta L, Pioli C, De Magistris MT.

Immunol Lett. 2008 Jan 15;115(1):59-69. Epub 2007 Nov 5.

PMID:
18031829
11.

Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP.

Vendetti S, Patrizio M, Riccomi A, De Magistris MT.

J Leukoc Biol. 2006 Oct;80(4):880-8. Epub 2006 Aug 3.

PMID:
16888088
12.

Zonula occludens toxin as a new promising adjuvant for mucosal vaccines.

De Magistris MT.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-60-1.

PMID:
16823929
13.

Mucosal delivery of vaccine antigens and its advantages in pediatrics.

De Magistris MT.

Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. Epub 2006 Mar 3. Review.

PMID:
16516335
14.

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

Marinaro M, Riccomi A, Rappuoli R, Pizza M, Fiorelli V, Tripiciano A, Cafaro A, Ensoli B, De Magistris MT.

Vaccine. 2003 Sep 8;21(25-26):3972-81.

PMID:
12922133
15.
16.
17.

Cyclic adenosine 5'-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.

Vendetti S, Riccomi A, Sacchi A, Gatta L, Pioli C, De Magistris MT.

J Immunol. 2002 Dec 1;169(11):6231-5.

18.

Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses.

Gagliardi MC, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris MT.

Int J Med Microbiol. 2002 Feb;291(6-7):571-5. Review.

PMID:
11892684
19.

Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines.

Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, Abrignani S, Rappuoli R, Grandi G.

Eur J Immunol. 2001 Dec;31(12):3816-24.

20.

The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles.

Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL, Ugozzoli M, Van Nest G, De Magistris MT, Bensi G.

Vaccine. 2000 Dec 8;19(9-10):1008-12.

PMID:
11137233
21.

Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming.

Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris MT.

Eur J Immunol. 2000 Aug;30(8):2394-403.

22.

Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.

Marinaro M, Di Tommaso A, Uzzau S, Fasano A, De Magistris MT.

Infect Immun. 1999 Mar;67(3):1287-91.

23.

NMR studies on the structure/function correlations of T-cell-epitope analogs from pertussis toxin.

Scarselli M, Esposito G, De Magistris MT, Domenighini M, Rappuoli R, Burroni G, Bernini A, Niccolai N.

Eur J Biochem. 1998 Jun 1;254(2):313-7.

24.

Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.

De Magistris MT, Pizza M, Douce G, Ghiara P, Dougan G, Rappuoli R.

Dev Biol Stand. 1998;92:123-6.

PMID:
9554265
25.

Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection.

Ghiara P, Rossi M, Marchetti M, Di Tommaso A, Vindigni C, Ciampolini F, Covacci A, Telford JL, De Magistris MT, Pizza M, Rappuoli R, Del Giudice G.

Infect Immun. 1997 Dec;65(12):4996-5002.

26.

Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.

Di Tommaso A, Bartalini M, Peppoloni S, Podda A, Rappuoli R, De Magistris MT.

Vaccine. 1997 Aug;15(11):1218-24.

PMID:
9286047
27.

Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4.

Finco O, Nuti S, De Magistris MT, Mangiavacchi L, Aiuti A, Forte P, Fantoni A, van der Putten H, Abrignani S.

Eur J Immunol. 1997 Jun;27(6):1319-24.

PMID:
9209479
28.

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.

Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, Douce G, De Magistris MT.

Infect Immun. 1996 Mar;64(3):974-9.

29.

The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.

Petre J, Pizza M, Nencioni L, Podda A, De Magistris MT, Rappuoli R.

Dev Biol Stand. 1996;87:125-34.

PMID:
8854009
30.

Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies.

Di Tommaso A, Xiang Z, Bugnoli M, Pileri P, Figura N, Bayeli PF, Rappuoli R, Abrignani S, De Magistris MT.

Infect Immun. 1995 Mar;63(3):1102-6.

31.

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.

Peppoloni S, Pizza M, De Magistris MT, Bartoloni A, Rappuoli R.

Physiol Chem Phys Med NMR. 1995;27(4):355-61. Review.

PMID:
8768791
32.

Development of the new acellular recombinant pertussis vaccine.

Rappuoli R, Pizza M, Podda A, De Magistris MT, Ceccarini C, Nencioni L.

Arch Inst Pasteur Tunis. 1994 Jul-Oct;71(3-4):557-63. No abstract available.

PMID:
8801858
33.

Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing.

di Tommaso A, de Magistris MT, Bugnoli M, Marsili I, Rappuoli R, Abrignani S.

Infect Immun. 1994 May;62(5):1830-4.

34.
35.

Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.

Rappuoli R, Pizza M, Covacci A, Bartoloni A, Nencioni L, Podda A, De Magistris MT.

FEMS Microbiol Immunol. 1992 Oct;5(4):161-70.

PMID:
1384602
36.
37.

Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones.

De Magistris MT, Di Tommaso A, Domenighini M, Censini S, Tagliabue A, Oksenberg JR, Steinman L, Judd AK, O'Sullivan D, Rappuoli R.

Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2990-4.

38.

Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor.

De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A.

Cell. 1992 Feb 21;68(4):625-34.

PMID:
1739971
39.

Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.

Rappuoli R, Pizza M, De Magistris MT, Podda A, Bugnoli M, Manetti R, Nencioni L.

Immunobiology. 1992 Feb;184(2-3):230-9. Review.

PMID:
1587545
40.

Progress towards the development of new vaccines against whooping cough.

Rappuoli R, Podda A, Pizza M, Covacci A, Bartoloni A, de Magistris MT, Nencioni L.

Vaccine. 1992;10(14):1027-32. Review.

PMID:
1471424
41.

Properties of the B oligomer of pertussis toxin.

Nencioni L, Pizza MG, Volpini G, De Magistris MT, Giovannoni F, Rappuoli R.

Infect Immun. 1991 Dec;59(12):4732-4.

42.

Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.

Podda A, Nencioni L, Marsili I, Peppoloni S, Volpini G, Donati D, Di Tommaso A, De Magistris MT, Rappuoli R.

Vaccine. 1991 Oct;9(10):741-5.

PMID:
1759492
43.

Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis.

Peppoloni S, Nencioni L, Di Tommaso A, Tagliabue A, Parronchi P, Romagnani S, Rappuoli R, De Magistris MT.

Infect Immun. 1991 Oct;59(10):3768-73.

44.

Identification of subregions of Bordetella pertussis filamentous hemagglutinin that stimulate human T-cell responses.

Di Tommaso A, Domenighini M, Bugnoli M, Tagliabue A, Rappuoli R, De Magistris MT.

Infect Immun. 1991 Sep;59(9):3313-5.

45.

Towards third-generation whooping cough vaccines.

Rappuoli R, Pizza M, Podda A, De Magistris MT, Nencioni L.

Trends Biotechnol. 1991 Jul;9(7):232-8. Review.

PMID:
1370047
46.

Human T cell immunity against Bordetella pertussis analyzed at clonal level.

De Magistris MT, Rappuoli R, Tagliabue A.

Ann Ist Super Sanita. 1991;27(1):33-6.

PMID:
1683526
47.

Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

Podda A, Nencioni L, De Magistris MT, Di Tommaso A, Bossù P, Nuti S, Pileri P, Peppoloni S, Bugnoli M, Ruggiero P, et al.

J Exp Med. 1990 Sep 1;172(3):861-8.

48.

Mutants of pertussis toxin suitable for vaccine development.

Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M, et al.

Science. 1989 Oct 27;246(4929):497-500.

PMID:
2683073
49.

Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map.

De Magistris MT, Romano M, Bartoloni A, Rappuoli R, Tagliabue A.

J Exp Med. 1989 May 1;169(5):1519-32.

50.

Natural antibacterial activity against Salmonella typhi in human cord blood.

Romano M, de Magistris MT, Villa L, Nuti S, de Leo V, Boraschi D, Nencioni L, Tagliabue A.

J Immunol. 1989 Apr 1;142(7):2513-8.

PMID:
2926143

Supplemental Content

Loading ...
Support Center